Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
Myeloproliferative neoplasms (MPNs) are blood disorders that occur when the body makes too
many white or red blood cells, or platelets. This overproduction of blood cells in the bone
marrow can create problems for blood flow and lead to various symptoms. One of the major
problems is the formation of blood clots. These may form in the veins of a patient's legs or
arms where they cause leg or arm pain, swelling or difficulty walking. These clots may travel
to the lung and then cause chest pain, shortness of breath and sometimes death. Blood clots
can also lead to poor or no blood flow to one's heart, brain, or other organs, causing
damages that cannot be easily or ever repaired, such as stroke or heart attack.
Patients diagnosed with certain types of MPN are associated with a higher risk of developing
blood clots and related complications. For this reason, MPN patients are usually treated with
low-dose aspirin, a common drug used for blood clot prevention, on long-term basis to prevent
the formation of blood clots and other complications. However, recent studies also show that
the risk of blood clots remains elevated in MPN patients treated with aspirin, and there may
not be improvement or reduction in fatal or other events that are associated with blood
clots. In addition, since this medical condition is rare, so there's a lack of studies done
with high quality results to help physicians decide the best treatment plan for these
patients.
The study drug, apixaban, is a new type of orally-taken blood thinner that has been shown to
be effective and safe for prevention and treatment of blood clots in various patient
populations. The investigators will evaluate whether apixaban is safer and/or better at
preventing blood clots and other complications in MPN patients compared to aspirin.
Phase:
Phase 2
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Canadian Society of Hematology Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network the Association médicale universitaire de l'Hôpital Montfort (AMUHM) the Association médicale universitaire de l’Hôpital Montfort (AMUHM)